Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Deucravacitinib for Sarcoidosis and Granuloma Annulare
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial aims to study the use of an oral medication that targets a specific protein in patients with a skin condition called sarcoidosis. The trial focuses on patients with moderate to severe sarcoidosis that
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service